SCHEMBL6567123

SCHEMBL6567123

c1ccc2c(c1)CCCc1nc(-c3ccc4c(c3)OCCO4)[nH]c1-2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 4/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
MAPT P10636 3/20 0.40
LMNA P02545 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
HDAC6 Q9UBN7 1/20 0.40
KDM4E B2RXH2 1/20 0.40
HTT P42858 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
TGFBR1 P36897 1/20 0.40
CSNK1A1 P48729 1/20 0.40
CSNK1D P48730 1/20 0.40
CSNK1E P49674 1/20 0.40
CSNK1G2 P78368 1/20 0.40
PRKD1 Q15139 1/20 0.40
MAPK14 Q16539 1/20 0.40
CSNK1G1 Q9HCP0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6835188 0.80 NPY5R (0.61) NPY5RKMT2AMAPK14NPC1RAB9A
SCHEMBL6836970 0.76 NPY5R (0.64) NPY5RALDH1A1KDM4EMAPK14CDK1
SCHEMBL6831691 0.73 NPY5R (0.66) NPY5RMEN1KMT2AMAPTALDH1A1
SCHEMBL6836941 0.73 ALDH1A1 (0.38) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL6837109 0.71 NPY5R (0.64) NPY5RKMT2AMAPTLMNAALDH1A1
SCHEMBL7395837 0.71 HDAC6 (0.59) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL6835211 0.68 NPY5R (0.66) NPY5RMEN1KMT2AMAPTLMNA
SCHEMBL347506 0.64 TNKS (0.85) MAPTALDH1A1HPGDKDM4EPARP1
SCHEMBL4053030 0.64 AURKA (0.45) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL6835593 0.63 NPY5R (0.34) NPY5RALDH1A1HPGDKDM4ETGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040198791-A1 Fused imidazole derivative FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-10-07 US disclosed
EP-1403256-A1 FUSED IMIDAZOLE DERIVATIVE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198791-A1 Fused imidazole derivative H1-0, H1-5, H1-3 NPY5R 983/4885MEN1 1176/4885KMT2A 1203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.